AU1801499A - Uses of p27 in prostate cancer - Google Patents

Uses of p27 in prostate cancer

Info

Publication number
AU1801499A
AU1801499A AU18014/99A AU1801499A AU1801499A AU 1801499 A AU1801499 A AU 1801499A AU 18014/99 A AU18014/99 A AU 18014/99A AU 1801499 A AU1801499 A AU 1801499A AU 1801499 A AU1801499 A AU 1801499A
Authority
AU
Australia
Prior art keywords
prostate cancer
prostate
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU18014/99A
Inventor
Carlos Cordon-Cardo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of AU1801499A publication Critical patent/AU1801499A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU18014/99A 1997-12-01 1998-12-01 Uses of p27 in prostate cancer Abandoned AU1801499A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6719097P 1997-12-01 1997-12-01
US60067190 1997-12-01
PCT/US1998/025483 WO1999028749A1 (en) 1997-12-01 1998-12-01 USES OF p27 IN PROSTATE CANCER

Publications (1)

Publication Number Publication Date
AU1801499A true AU1801499A (en) 1999-06-16

Family

ID=22074317

Family Applications (1)

Application Number Title Priority Date Filing Date
AU18014/99A Abandoned AU1801499A (en) 1997-12-01 1998-12-01 Uses of p27 in prostate cancer

Country Status (2)

Country Link
AU (1) AU1801499A (en)
WO (1) WO1999028749A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972170B1 (en) 1997-12-01 2005-12-06 Sloan-Kettering Institute For Cancer Research Markers for prostate cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688665A (en) * 1994-01-07 1997-11-18 Fred Hutchinson Cancer Research Center Isolated nucleic acid molecules encoding the p27 KIP-1 protein

Also Published As

Publication number Publication date
WO1999028749A1 (en) 1999-06-10

Similar Documents

Publication Publication Date Title
AU7961198A (en) Towable carrying case
AU3583797A (en) Enhancement of cancer cell death
AU1773699A (en) Antenna
AU6229098A (en) Cancer-associated genes
IL136167A0 (en) Conjugates useful in the treatment of prostate cancer
AU1520499A (en) Essential fungal genes and their use
AU6537798A (en) Targeted cytolysis of cancer cells
AU9018598A (en) Prognostic compositions for prostate cancer and methods of use thereof
AU6111800A (en) 26 human prostate and prostate cancer associated proteins
AUPO492397A0 (en) Prostate specific promoters
AU1268999A (en) Single-frequency antenna arrangement
AU2297201A (en) Uses of antileukoprotease in carcinoma
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
AU1538499A (en) Body ornament
AU8074698A (en) (costal2) genes and their uses
GB9703633D0 (en) Cancer therapy
AU1801499A (en) Uses of p27 in prostate cancer
AU5316099A (en) Prostate cancer assays and related methods
AU3349997A (en) Reg gene expression in cancer tissue
AU4860299A (en) (zap-3) tumor associated genes and their uses
AU6084598A (en) Antibiotic-ligand conjugates and methods of use thereof
AU5778698A (en) Reduction of restenosis
AU4417996A (en) Treatment of prostate cancer
AU1685899A (en) Antenna
AU1045199A (en) Cancer gene

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase